The present disclosure relates to a vaccine composition for preventing human infection SARS-CoV-2 (COVID-19) and alleviating infection symptoms, and the vaccine composition including a recombinant Newcastle disease virus on the surface of which the SARS-CoV-2 RBD protein of the present disclosure is expressed or antigen purified therefrom induces an immune response that can fight COVID-19 infection so that it can be useful as a vaccine for preventing and treating SARS-CoV-2 infection.

Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.

Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein in RSV and inactivated RSV virus obtained thereby. Also provided are a vaccine comprising the inactivated RSV virus and a use of the vaccine in preventing or treating RSV infection or a disease related thereto.

The invention relates to the field of veterinary medicine. The invention provides an immunogenic composition, comprising a hemagglutinin protein of avian influenza virus H5 subtype. Also provided is a method of differentiating animals naturally infected with AIV from animals vaccinated with the immunogenic composition of the invention. The immunogenic composition of the invention can provide a broader, more effective, long-lasting and early onset protection on poultry.

The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

The present disclosure relates to a fully liquid immunogenic composition comprising a combination of antigens/immunogens. The immunogenic composition comprises optimum amount of antigens/immunogens to confer protection against a number of diseases. The composition exhibits improved immunogenicity and stability. A process for preparing the vaccine composition is also disclosed.

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

The current disclosure describes the use of NFkB inhibitors as immune potentiators in vaccine compositions comprising adjuvants. Accordingly, aspects of the disclosure relate to a method for vaccinating a subject comprising administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Further aspects relate to a method for inhibiting an inflammatory reaction associated with an adjuvant in a subject, the method comprising co-administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Yet further aspects relate to a pharmaceutical composition comprising a NFkB inhibitor and an adjuvant.